Highlights Pharnext SCA

Equities

ALPHA

FR001400N1P4

Market Closed - Euronext Paris Other stock markets 16:20:54 28/06/2024 BST			5-day change	1st Jan Change
0.0079 ^EUR	-14.13%		-38.28%	-99.60%

06-28	Pharnext: deadlock with Tasly, share price falls	CF
06-19	Pharnext: conciliation procedure extended	CF

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pharnext: deadlock with Tasly, share price falls	06-28	CF
Pharnext: share price rises on encouraging comments	04-25	CF
Pharnext: listing suspended pending further update	03-06	CF
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	02-21
Pharnext launches drastic cost-cutting plan	01-17	CF
Pharnext Delays Exclusivity Agreement for Peripheral Nerve Disease Drug; Shares Sink	11-27	MT
Pharnext Manufactures US Registration Batches of Oral Solution Ahead of FDA Application	11-20	MT
Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2023	30/10/23	CI
Pharnext Shares Soar on EUR510 Million Offer for Neuropathy Drug Candidate	30/10/23	MT
Neovacs: boosted by the Pharnext dossier	23/10/23	CF
Pharnext Shares Surge Amid EUR250 Million Offers for Main Drug Candidate	16/10/23	MT
Pharnext SA Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23	CI
Pharnext: Edison analysts to value the company	06/01/23	CF
Pharnext: Edison commissioned to value the company	05/01/23	CF
Pharnext Soars 63% on Increased Funding Commitment of Néovacs	29/12/22	MT
Pharnext Strengthens Its Ties with Néovacs to Secure the Next Steps in Its Development	28/12/22	CI
Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2022	17/10/22	CI
Pharnext SA Announces the Publication of Symptom Burden Findings of Charcot-Marie-Tooth Disease Type1a ("Cmt1a") from the ‘Real-World' Digital Lifestyle Study, CMT&Me, in the Journal of Clinical Neuromuscular Disease	14/09/22	CI
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial	12/09/22	CI
Pharnext Soars 13% On Potential $20 Million Investment From Neovacs	08/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pharnext SCA

Equities

ALPHA

FR001400N1P4

Highlights

Filters